close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Phathom Pharmaceuticals

< Previous 1 2 3 Next >
News headline image
Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers HTGC PHAT
News headline image
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports First Quarter 2023 Results
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Provides Regulatory Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
Tickers PHAT
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today